Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2004 2
2007 2
2008 2
2012 1
2016 1
2017 1
2018 1
2021 1
2022 2
2023 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis.
Young CA, Rog DJ, Sharrack B, Tanasescu R, Kalra S, Harrower T, Tennant A, Mills RJ; Trajectories of Outcome in Neurological Conditions-MS Study Group. Young CA, et al. Neurol Sci. 2024 May;45(5):2181-2189. doi: 10.1007/s10072-023-07155-3. Epub 2023 Nov 17. Neurol Sci. 2024. PMID: 37976012 Free PMC article.
Measuring coping in multiple sclerosis: The Coping Index-MS.
Young CA, Mills RJ, Langdon D, Rog DJ, Sharrack B, Kalra S, Majeed T, Footit D, Harrower T, Nicholas RS, Ford HL, Woolmore J, Johnstone C, Thorpe J, Paling D, Ellis C, Hanneman CO, Tennant A. Young CA, et al. Among authors: woolmore j. Mult Scler. 2022 Dec;28(14):2274-2284. doi: 10.1177/13524585221114004. Epub 2022 Aug 24. Mult Scler. 2022. PMID: 36000480
Prevalence, treatment and correlates of depression in multiple sclerosis.
Young CA, Langdon D, Rog D, Chhetri SK, Tanasescu R, Kalra S, Webster G, Nicholas R, Ford HL, Woolmore J, Paling D, Tennant A, Mills R; TONiC study group. Young CA, et al. Among authors: woolmore j. Mult Scler Relat Disord. 2024 Jul;87:105648. doi: 10.1016/j.msard.2024.105648. Epub 2024 Apr 26. Mult Scler Relat Disord. 2024. PMID: 38713965 Free article.
The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications.
Young CA, Mills R, Langdon D, Sharrack B, Majeed T, Kalra S, Footitt D, Rog D, Harrower T, Nicholas R, Woolmore J, Thorpe J, Hanemann CO, Ford H, Paling D, Ellis C, Palace J, Constantinescu C, Tennant A. Young CA, et al. Among authors: woolmore j. J Neurol Sci. 2022 May 15;436:120188. doi: 10.1016/j.jns.2022.120188. Epub 2022 Feb 18. J Neurol Sci. 2022. PMID: 35303502
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
15 results